HHS Public Access Author manuscript Author Manuscript
Biomed Pharmacother. Author manuscript; available in PMC 2017 August 11. Published in final edited form as: Biomed Pharmacother. 2017 June ; 90: 665–669. doi:10.1016/j.biopha.2017.04.008.
Cost-benefit effectiveness of angiotensin-II receptor blockers in patients with uncomplicated hypertension: A comparative analysis
Author Manuscript
Alberto Mazzaa,*, Antonella Paola Saccob, Danyelle M. Townsendc, Gianni Bregolad, Edgardo Contattoe, Isabella Cappellof, Laura Schiavong, Emilio Laurag, and Domenico Rubelloh aHypertension
Centre certified by the Italian Society of Hypertension, Hospital Santa Maria della Misericordia, Rovigo, Italy
bUnit
of Internal Medicine, Department of Medicine, Hospital Santa Maria della Misericordia, Rovigo, Italy cDepartment
of Drug Discovery and Pharmaceutical Sciences, Medical University of South Carolina, USA dHospital
Santa Maria della Misericordia, Rovigo, Italy
eAzienda
ULSS 5 Polesana, Rovigo, Italy
fMorosini
Integrated Medicine, Azienda ULSS 5 Polesana, Rovigo, Italy
Author Manuscript
gDepartment
of Medicine, Hospital Santa Maria della Misericordia, Rovigo, Italy
hDepartement
of Nuclear Medicine, Hospital Santa Maria della Misericordia, Rovigo, Italy
Abstract Objective—The treatment of hypertensive patients (HTs) requires a long-term commitment of compliance for the patient and resources by the healthcare system. This poses an economic dilemma in countries where universal healthcare is standard. The aim of this study was to evaluate the costs/health benefit and effectiveness of treatment with angiotensin-II receptor blockers (ARBs) in uncomplicated essential hypertension.
Author Manuscript
Design and methods—The daily and annual economic commitment for treating patients with ARBs was estimated using pharmacy dispensing records and the BP-lowering effects of candesartan, irbesartan, losartan, olmesartan, telmisartan and valsartan was evaluated retrospectively. In 114 HTs (mean age 59.4 ± 13.5 year, 57.5% men), the BP-lowering effect of ARBs as in monotherapy and in fixed-dose combination (FDC) with hydrochlorothiazide at the doses commonly used in the market to reach BP control (i.e. BP
Biomed Pharmacother. Author manuscript; available in PMC 2017 August 11. Published in final edited form as: Biomed Pharmacother. 2017 June ; 90: 665–669. doi:10.1016/j.biopha.2017.04.008.
Cost-benefit effectiveness of angiotensin-II receptor blockers in patients with uncomplicated hypertension: A comparative analysis
Author Manuscript
Alberto Mazzaa,*, Antonella Paola Saccob, Danyelle M. Townsendc, Gianni Bregolad, Edgardo Contattoe, Isabella Cappellof, Laura Schiavong, Emilio Laurag, and Domenico Rubelloh aHypertension
Centre certified by the Italian Society of Hypertension, Hospital Santa Maria della Misericordia, Rovigo, Italy
bUnit
of Internal Medicine, Department of Medicine, Hospital Santa Maria della Misericordia, Rovigo, Italy cDepartment
of Drug Discovery and Pharmaceutical Sciences, Medical University of South Carolina, USA dHospital
Santa Maria della Misericordia, Rovigo, Italy
eAzienda
ULSS 5 Polesana, Rovigo, Italy
fMorosini
Integrated Medicine, Azienda ULSS 5 Polesana, Rovigo, Italy
Author Manuscript
gDepartment
of Medicine, Hospital Santa Maria della Misericordia, Rovigo, Italy
hDepartement
of Nuclear Medicine, Hospital Santa Maria della Misericordia, Rovigo, Italy
Abstract Objective—The treatment of hypertensive patients (HTs) requires a long-term commitment of compliance for the patient and resources by the healthcare system. This poses an economic dilemma in countries where universal healthcare is standard. The aim of this study was to evaluate the costs/health benefit and effectiveness of treatment with angiotensin-II receptor blockers (ARBs) in uncomplicated essential hypertension.
Author Manuscript
Design and methods—The daily and annual economic commitment for treating patients with ARBs was estimated using pharmacy dispensing records and the BP-lowering effects of candesartan, irbesartan, losartan, olmesartan, telmisartan and valsartan was evaluated retrospectively. In 114 HTs (mean age 59.4 ± 13.5 year, 57.5% men), the BP-lowering effect of ARBs as in monotherapy and in fixed-dose combination (FDC) with hydrochlorothiazide at the doses commonly used in the market to reach BP control (i.e. BP
